Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company advancing targeted therapies for endocrine-driven breast cancers. This page provides investors and healthcare professionals with timely updates on clinical developments, financial disclosures, and strategic initiatives.
Access consolidated information about OLMA's lead candidate palazestrant (OP-1250), an oral complete estrogen receptor antagonist/SERD, and other pipeline assets like the KAT6 inhibitor OP-3136. Track regulatory milestones, partnership announcements, and peer-reviewed research findings in one centralized location.
Key updates include clinical trial progress, scientific conference presentations, and financial results. All content is sourced from official company communications and verified industry reports to ensure accuracy.
Bookmark this page for streamlined access to OLMA's latest developments in women's oncology therapeutics. Check regularly for essential updates impacting treatment innovation and corporate strategy.
Olema Oncology announced interim results from a Phase 1b/2 study of palazestrant (OP-1250) combined with ribociclib for ER+/HER2- metastatic breast cancer at the 2024 ESMO Breast Cancer Congress. Across 50 patients, the combination therapy was well tolerated, showing no new safety signals and maintaining an 85% clinical benefit rate (CBR). Pharmacokinetics demonstrated high oral bioavailability and consistent inhibition of estrogen receptors, with no significant drug interaction between palazestrant and ribociclib. The study included patients with advanced cancer, many of whom had received prior treatments. The company will discuss these findings in a webcast on May 15, 2024.
Olema Oncology reported its first quarter 2024 financial results and provided a corporate update, highlighting the completion of enrollment in Phase 1b/2 clinical studies of palazestrant in combination with ribociclib and palbociclib. New clinical data from the palazestrant-ribociclib combination study will be presented at the ESMO Breast Cancer Annual Congress 2024. The company also announced the IND application for OP-3136, a novel KAT6 inhibitor, expected to be filed with the FDA in late 2024. Olema Pharmaceuticals reported a cash position of $249.0 million as of March 31, 2024.
Olema Pharmaceuticals, Inc. announces new clinical data for Palazestrant in combination with Ribociclib to be presented at the 2024 ESMO Breast Cancer Annual Congress. The company will share information from its ongoing Phase 1b/2 clinical study in a poster presentation. The event will take place in Berlin, Germany, on May 15-17, 2024.
Additionally, Olema will host an investor conference call on May 15, 2024, to discuss the data further. The company focuses on developing targeted therapies for women's cancers, marking a significant milestone in its research and development efforts.
Olema Pharmaceuticals, Inc. announced the granting of stock options to new employees under the Company's 2022 Inducement Plan. A total of 187,400 shares of common stock were granted to six employees, with options vesting over four years. The exercise price is set at $10.40 per share, with the options subject to Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) will participate in various investor conferences in May, including the BofA Securities Health Care Conference, H.C. Wainwright BioConnect Investor Conference, UBS Spring Biotech Symposium, and TD Cowen Oncology Innovation Summit. The management team will engage in presentations, fireside chats, and one-on-one meetings to discuss the company's targeted therapies for women's cancers.
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
